SLC5A2 and obstructive sleep apnea syndrome: Second, the constraints of covariates (key cardiovascular metabolic drugs, especially newer drugs such as GLP-1 receptor agonists and SGLT2 inhibitors), may simultaneously affect CMI and OSA.